Thermo Fisher Scientific to continue focusing on SARS-CoV2 diagnostic solutions: Amit Chopra

Our endeavor has always been to develop innovative, adaptive, and resilient testing solutions that leverage our capabilities to address the public health crisis, says Amit Chopra, Managing Director, India and South Asia, Thermo Fisher Scientific

0
312
New Delhi: “Thermo Fisher Scientific has been intensely focused for the past 19 months, predominantly in the development of diagnostic testing capabilities in the response to the pandemic. As the pandemic evolves, we are developing additional technologies to support our customers and society in the near- and long term,” says Amit Chopra, Managing Director, India and South Asia, Thermo Fisher Scientific in his year ending comment.
“We have been aware that, like most viruses, SARS-CoV-2 would continue to mutate and that effective testing strategies would be a key to curbing the pandemic. In addition, testing plays a crucial role in making informed decisions and reducing transmissions. With this backdrop, our TaqPath Assays are developed to ensure that clinicians, researchers, and public health officials have access to effective tools to accurately detect COVID-19, even as the virus continues to mutate and evolve,” added Mr. Chopra.
Mr. Chopra while highlighting one of the highly focused diagnostic solution at the moment, said “Additionally, Thermo Fisher’s point of care solution- Accula system, a rapid test that uses PCR technology- the gold standard in testing, provides accurate results in 30 minutes. The Accula SARS-CoV-2 Test has received emergency use authorization (EUA) from the United States Food and Drug Administration (FDA) for detection of SARS-CoV-2 in Clinical Laboratory Improvement Amendments (CLIA)-waived environments. It has now been successfully demonstrated for its efficacy in detecting the Omicron variant without any impact on the quality of the test. The Accula SARS-CoV-2 Test will help meet the continuing demands for rapid and reliable COVID-19 testing, especially at airports, hospitals, and other places of public gathering.”
“At Thermo Fisher, our endeavor has always been to develop innovative, adaptive, and resilient testing solutions that leverage our capabilities to address the public health crisis. We are committed to innovating and delivering products that prevent the spread of this disease and protect communities. As we advance, we will continue with our promise and expand our high-quality solutions with accelerated innovation to help the world move forward,” Mr. Chopra said in his future outlook statement.